Preserving cognitive function in patients with Alzheimer's disease: The Alzheimer's disease neuroprotection research initiative (ADNRI).

Autor: Liu J; Department of Neurology, Daping Hospital Third Military Medical University Chongqing China.; Chongqing Key Laboratory of Ageing and Brain Diseases Chongqing China., van Beusekom H; Division of Experimental Cardiology, Department of Cardiology, Erasmus MC University Medical Center Rotterdam The Netherlands., Bu XL; Department of Neurology, Daping Hospital Third Military Medical University Chongqing China.; Chongqing Key Laboratory of Ageing and Brain Diseases Chongqing China.; Institute of Brain and Intelligence Third Military Medical University Chongqing China., Chen G; Guangdong-HongKong-Macau Institute of CNS Regeneration (GHMICR) Jinan University Guangzhou Guangdong China., Henrique Rosado de Castro P; Institute of Biomedical Sciences Federal University of Rio de Janeiro Rio de Janeiro Rio de Janeiro Brazil., Chen X; Fujian Key Laboratory of Molecular Neurology, Department of Neurology and Geriatrics, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, Institute of Neuroscience Fujian Medical University Fuzhou Fujian China., Chen X; Institute of Brain and Intelligence Third Military Medical University Chongqing China.; Guangyang Bay Laboratory Chongqing Institute for Brain and Intelligence Chongqing China.; Center for Excellence in Brain Science and Intelligence Technology Chinese Academy of Sciences Shanghai China., Clarkson AN; Department of Anatomy, Brain Health Research Centre and Brain Research New Zealand University of Otago Dunedin New Zealand., Farr TD; School of Life Sciences University of Nottingham Nottingham UK., Fu Y; Brain and Mind Centre & School of Medical Sciences The University of Sydney Sydney New South Wales Australia., Jia J; Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, National Clinical Research Center for Geriatric Diseases Capital Medical University Beijing China., Jolkkonen J; A.I. Virtanen Institute for Molecular Sciences University of Eastern Finland Kuopio Finland., Kim WS; Brain and Mind Centre & School of Medical Sciences The University of Sydney Sydney New South Wales Australia., Korhonen P; A.I. Virtanen Institute for Molecular Sciences University of Eastern Finland Kuopio Finland., Li S; Department of Neurology and Psychiatry, Beijing Shijitan Hospital Capital Medical University Beijing China., Liang Y; Department of Diagnostic Radiology and Nuclear Medicine University of Maryland School of Medicine Baltimore Maryland USA., Liu GH; University of Chinese Academy of Sciences Beijing China.; State Key Laboratory of Membrane Biology, Institute of Zoology Chinese Academy of Sciences Beijing China., Liu G; Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders Capital Medical University Beijing China., Liu YH; Department of Neurology, Daping Hospital Third Military Medical University Chongqing China.; Chongqing Key Laboratory of Ageing and Brain Diseases Chongqing China.; Institute of Brain and Intelligence Third Military Medical University Chongqing China., Malm T; A.I. Virtanen Institute for Molecular Sciences University of Eastern Finland Kuopio Finland., Mao X; Institute for Cell Engineering, Department of Neurology The Johns Hopkins University School of Medicine Baltimore Maryland USA., Oliveira JM; 3B's Research Group, I3Bs-Research Institute on Biomaterials, Biodegradables and Biomimetics, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine University of Minho Guimarães Portugal.; ICVS/3B's-PT Government Associate Laboratory Braga/Guimarães Portugal., Modo MM; Department of Bioengineering, McGowan Institute for Regenerative Medicine University of Pittsburgh Pittsburgh Pennsylvania USA.; Department of Radiology, McGowan Institute for Regenerative Medicine University of Pittsburgh Pittsburgh Pennsylvania USA., Ramos-Cabrer P; Magnetic Resonance Imaging Laboratory CIC BiomaGUNE Research Center, Basque Research and Technology Alliance (BRTA) Donostia-San Sebastian Spain., Ruscher K; Laboratory for Experimental Brain Research, Division of Neurosurgery, Department of Clinical Sciences Lund University Lund Sweden., Song W; Institute of Aging, Key Laboratory of Alzheimer's Disease of Zhejiang Province. Zhejiang Clinical Research Center for Mental Disorders, School of Mental Health and The Affiliated Kangning Hospital, Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health) Wenzhou Medical University Zhejiang China., Wang J; Department of Neurology, Daping Hospital Third Military Medical University Chongqing China.; Chongqing Key Laboratory of Ageing and Brain Diseases Chongqing China., Wang X; School of Optometry and Vision Science University of New South Wales Sydney New South Wales Australia., Wang Y; Neuroscience Research Institute, Department of Neurobiology, School of Basic, Medical Sciences, Key Laboratory for Neuroscience, Ministry of Education/National, Health Commission and State Key Laboratory of Natural and Biomimetic Drugs Peking University Beijing China.; PKU-IDG/McGovern Institute for Brain Research Peking University Beijing China., Wu H; Department of Neurobiology Beijing Institute of Basic Medical Sciences Beijing China., Xiong L; Shanghai Key Laboratory of Anesthesiology and Brain Functional Modulation, Clinical Research Center for Anesthesiology and Perioperative Medicine, Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People's Hospital, School of Medicine Tongji University Shanghai China., Yang Y; Department of Neurology The First Hospital of Jilin University, Chang Chun Jilin China., Ye K; Faculty of Life and Health Sciences Brain Cognition and Brain Disease Institute (BCBDI), Shenzhen Institute of Advanced Technology Shenzhen China., Yu JT; State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College Fudan University Shanghai China., Zhou XF; Division of Health Sciences, School of Pharmacy and Medical Sciences and Sansom Institute University of South Australia Adelaide South Australia Australia.; Suzhou Auzone Biotech Suzhou Jiangsu China., Zille M; Department of Pharmaceutical Sciences, Division of Pharmacology and Toxicology University of Vienna Vienna Austria., Masters CL; The Florey Institute The University of Melbourne, Parkville Victoria Australia., Walczak P; Department of Diagnostic Radiology and Nuclear Medicine University of Maryland School of Medicine Baltimore Maryland USA., Boltze J; School of Life Sciences The University of Warwick Coventry UK., Ji X; Department of Neurosurgery Xuanwu Hospital, Capital Medical University Beijing China., Wang YJ; Department of Neurology, Daping Hospital Third Military Medical University Chongqing China.; Chongqing Key Laboratory of Ageing and Brain Diseases Chongqing China.; Institute of Brain and Intelligence Third Military Medical University Chongqing China.; Guangyang Bay Laboratory Chongqing Institute for Brain and Intelligence Chongqing China.; Center for Excellence in Brain Science and Intelligence Technology Chinese Academy of Sciences Shanghai China.
Jazyk: angličtina
Zdroj: Neuroprotection [Neuroprotection] 2023 Dec; Vol. 1 (2), pp. 84-98. Date of Electronic Publication: 2023 Sep 21.
DOI: 10.1002/nep3.23
Abstrakt: The global trend toward aging populations has resulted in an increase in the occurrence of Alzheimer's disease (AD) and associated socioeconomic burdens. Abnormal metabolism of amyloid-β (Aβ) has been proposed as a significant pathomechanism in AD, supported by results of recent clinical trials using anti-Aβ antibodies. Nonetheless, the cognitive benefits of the current treatments are limited. The etiology of AD is multifactorial, encompassing Aβ and tau accumulation, neuroinflammation, demyelination, vascular dysfunction, and comorbidities, which collectively lead to widespread neurodegeneration in the brain and cognitive impairment. Hence, solely removing Aβ from the brain may be insufficient to combat neurodegeneration and preserve cognition. To attain effective treatment for AD, it is necessary to (1) conduct extensive research on various mechanisms that cause neurodegeneration, including advances in neuroimaging techniques for earlier detection and a more precise characterization of molecular events at scales ranging from cellular to the full system level; (2) identify neuroprotective intervention targets against different neurodegeneration mechanisms; and (3) discover novel and optimal combinations of neuroprotective intervention strategies to maintain cognitive function in AD patients. The Alzheimer's Disease Neuroprotection Research Initiative's objective is to facilitate coordinated, multidisciplinary efforts to develop systemic neuroprotective strategies to combat AD. The aim is to achieve mitigation of the full spectrum of pathological processes underlying AD, with the goal of halting or even reversing cognitive decline.
Competing Interests: Xunming Ji, Johannes Boltze, and Piotr Walczak are the Editors‐in‐Chief, and Heleen van Beusekom, Andrew N. Clarkson, Paulo Henrique Rosado de Castro, Tracy D. Farr, Jukka Jolkkonen, Shen Li, Yajie Liang, Guiyou Liu, Xiaobo Mao, Joaquim Miguel Oliveira, Mike M. Modo, Pedro Ramos‐Cabrer, Karsten Ruscher, Yun Wang, Haitao Wu, Lize Xiong, Yi Yang, Marietta Zille, and Yan‐Jiang Wang are the editorial members, of Neuroprotection. They are therefore excluded from the peer‐review process and all editorial decisions related to the publication of this manuscript. The remaining authors declare no conflict of interest.
(© 2023 The Authors. Neuroprotection published by John Wiley & Sons Ltd on behalf of Chinese Medical Association.)
Databáze: MEDLINE
Externí odkaz: